Skip to main content
SpringerLink
Log in

Kein Überlebensvorteil trotz verzögerter Progression

Bevacizumab und Irinotecan in der Primärtherapie bei Glioblastomen mit unmethyliertem MGMT-Promotor

No Survival benefit despite sustained progression

Bevacizumab and irinotecan in the primary treatment for glioblastoma with non-methylated MGMT promoter

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versusradiotherapy alone on survival in glioblastoma in a randomised phase III study: 5‑year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. doi:10.1016/S1470-2045(09)70025-7

    Article  CAS  PubMed  Google Scholar 

  2. Hegi ME, Diserens A‑C, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. doi:10.1056/NEJMoa043331

    Article  CAS  PubMed  Google Scholar 

  3. Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722. doi:10.1056/NEJMoa1308345

    Article  CAS  PubMed  Google Scholar 

  4. Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. doi:10.1056/NEJMoa1308573

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Dirven L, Bent MJ van den, Bottomley A et al (2015) The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer 51:1321–1330. doi:10.1016/j.ejca .2015.03.025

    Article  CAS  PubMed  Google Scholar 

  6. Taphoorn MJB, Henriksson R, Bottomley A et al (2015) Health-related quality of life in a randomized phase III study of Bevacizumab, Temozolomide, and radiotherapy in newly diagnosed Glioblastoma. J Clin Oncol 33:2166–2175. doi:10.1200/JCO.2014.60.3217

    Article  CAS  PubMed  Google Scholar 

  7. Sandmann T, Bourgon R, Garcia J et al (2015) Patients with Proneural Glioblastoma may derive overall survival benefit from the addition of Bevacizumab to first-line radiotherapy and Temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol 33:2735–2744. doi:10.1200/JCO.2015.61.5005

    Article  CAS  PubMed  Google Scholar 

  8. Chinot OL, Nishikawa R, Mason W et al (2016) Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro Oncol. doi:10.1093/neuonc/now046

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Leipzig, Stephanstr. 9 a, 04103, Leipzig, Deutschland

    C. Seidel

Authors
  1. C. Seidel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Seidel.

Ethics declarations

Interessenkonflikt

C. Seidel hat ein Referenten-Honorar für die Teilnahme an Advisory Boards der Firma Roche erhalten.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seidel, C. Kein Überlebensvorteil trotz verzögerter Progression . Onkologe 22, 697–698 (2016). https://doi.org/10.1007/s00761-016-0076-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-016-0076-7

Search

Navigation